Aro Biotherapeutics Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
49
- Latest Deal Type
-
Later Stage VC
- Investors
-
10
Aro Biotherapeutics General Information
Description
Developer of tissue-targeted genetic medicines designed to address previously intractable diseases using a proprietary protein technology. The company's drugs are small, non-antibody protein scaffolds that can be expressed as multi-specifics with therapeutic mechanisms of action for non-small cell lung cancer, enabling physicians to achieve efficacy and safety profiles for patients with cancer and other serious diseases.
Contact Information
Website
www.arobiotx.comCorporate Office
- 601 Walnut Street
- Suite 740
- Philadelphia, PA 19106
- United States
Corporate Office
- 601 Walnut Street
- Suite 740
- Philadelphia, PA 19106
- United States
Aro Biotherapeutics Timeline
Aro Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC | 01-Jan-2025 | Completed | Clinical Trials - Phase 1 | |||
| 2. Later Stage VC (Series B) | 28-Nov-2023 | Completed | Clinical Trials - Phase 1 | |||
| 1. Early Stage VC (Series A) | 23-Nov-2021 | $90.3M | $90.3M | Completed | Clinical Trials - Phase 1 |
Aro Biotherapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A-2 | ||||||||
| Series A-1 | 15,160,970 | $0.001000 | 8% | $4.97 | $4.97 | 1x | $4.97 | 26.56% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Aro Biotherapeutics Comparisons
Industry
Financing
Details
Aro Biotherapeutics Competitors (60)
One of Aro Biotherapeutics’s 60 competitors is AnTolRx, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| AlphaVax | Formerly VC-backed | Durham, NC | ||||
| Amal Therapeutics | Formerly VC-backed | Geneva, Switzerland | ||||
| Abliva | Formerly VC-backed | Lund, Sweden | ||||
| Immunitas Therapeutics | Formerly VC-backed | Boston, MA |
Aro Biotherapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aro Biotherapeutics Patents
Aro Biotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026178229-A1 | Fn3 domain-ifih1 sirna conjugates and uses thereof | Pending | 19-Feb-2025 | ||
| WO-2025250964-A1 | Cd206 binding human fibronectin type iii protein scaffolds | Pending | 31-May-2024 | ||
| WO-2025245474-A1 | Formulations comprising fn3-sirna conjugates and uses thereof | Pending | 23-May-2024 | ||
| WO-2025231388-A1 | Methods and compositions for treating pompe disease | Pending | 03-May-2024 | ||
| EP-4605016-A2 | Cd71 binding fibronectin type iii domains | Pending | 19-Oct-2022 | C12N15/1138 |
Aro Biotherapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aro Biotherapeutics Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Avego Management | PE/Buyout | Minority | ||
| Blue Owl Credit Income Corp. BDC | Lender/Debt Provider | Minority | ||
| BVF Partners | Hedge Fund | Minority | ||
| Cowen Healthcare Investments | Venture Capital | Minority | ||
| HealthCap | Venture Capital | Minority |
Aro Biotherapeutics FAQs
-
When was Aro Biotherapeutics founded?
Aro Biotherapeutics was founded in 2018.
-
Where is Aro Biotherapeutics headquartered?
Aro Biotherapeutics is headquartered in Philadelphia, PA.
-
What is the size of Aro Biotherapeutics?
Aro Biotherapeutics has 49 total employees.
-
What industry is Aro Biotherapeutics in?
Aro Biotherapeutics’s primary industry is Biotechnology.
-
Is Aro Biotherapeutics a private or public company?
Aro Biotherapeutics is a Private company.
-
What is Aro Biotherapeutics’s current revenue?
The current revenue for Aro Biotherapeutics is .
-
How much funding has Aro Biotherapeutics raised over time?
Aro Biotherapeutics has raised $132M.
-
Who are Aro Biotherapeutics’s investors?
Avego Management, Blue Owl Credit Income Corp. BDC, BVF Partners, Cowen Healthcare Investments, and HealthCap are 5 of 10 investors who have invested in Aro Biotherapeutics.
-
Who are Aro Biotherapeutics’s competitors?
AnTolRx, AlphaVax, Amal Therapeutics, Abliva, and Immunitas Therapeutics are some of the 60 competitors of Aro Biotherapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
